arch43
EN_01454483_1507
Nita Patel, the Senior Director of Antibody Discovery and Vaccine Development, holds up a 96 Well Elisa Plate inside of a Novavax lab. Novavax is one of just seven vaccine makers to receive funding from Operation Warp Speed, the U.S. government program designed to quickly produce 300 million doses of COVID-19 vaccines. Compared to the other pharmaceutical firms in Operation Warp Speed, it's a small company with a unique approach that relies on cells from moths to act as vaccine factories.
MINIMUM PRICE $100
2020-10-20
Alyssa Schukar/Redux/Redux Pictures/East News
Redux Pictures
Alyssa Schukar/Redux
15454271
2,97MB
36cm x 24cm by 300dpi
300, 96, A, ACT, ALYSSA, AND, ANTIBODY, APPROACH, AS, CELLS, COMPANY, COMPARED, CORONOAVIRUS, COVID, COVID-19, DESIGNED, DEVELOPMENT, DIRECTOR, DISCOVERY, DOSES, ELISA, FACTORIES, FIRMS, FROM, FUNDING, GOVERNMENT, HOLDS, IN, INSIDE, IS, IT, JUST, LAB, MAKERS, MEDICAL, MEDICINE, MILLION, MOTHS, NITA, NOVAVAX, OF, ON, ONE, OPERATION, OTHER, PANDEMIC, PATEL, PHARMACEUTICAL, PLATE, PRODUCE, PROGRAM, QUICKLY, RECEIVE, REDUX, RELIES, RESEARCH, RESSEARCH, SCHUKAR, SCIENCE, SENIOR, SEVEN, SMALL, SPEED, THAT, THE, TO, U, UNIQUE, UP, VACCINE, VACCINES, WARP, WELL, WITH, WORKER, WORKERS, WORKING,